OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 223.4% in July

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 135,370 shares, a growth of 223.4% from the July 15th total of 41,862 shares. Based on an average daily volume of 144,700 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of OKYO Pharma in the 4th quarter valued at about $36,000. Renaissance Technologies LLC grew its stake in OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares during the period. Finally, Citadel Advisors LLC bought a new stake in OKYO Pharma in the third quarter worth approximately $31,000. 2.97% of the stock is owned by institutional investors.

OKYO Pharma Trading Up 0.3%

Shares of NASDAQ OKYO traded up $0.01 during trading on Thursday, reaching $1.51. The company had a trading volume of 8,695 shares, compared to its average volume of 161,647. The company’s fifty day moving average price is $1.56 and its 200-day moving average price is $1.66. OKYO Pharma has a 12 month low of $1.34 and a 12 month high of $3.20.

Analyst Ratings Changes

Several research analysts have recently issued reports on OKYO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Friday, July 17th. HC Wainwright decreased their price target on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.67.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.